Elisabeth-Krankenhaus

Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial (2023) Williams TM, Schneeweiss A, Jackisch C, Shen C, Weber KE, Fasching P, Denkert C, et al. Journal article Multicentric validation of a comprehensive geriatric assessment to predict functional outcome and mortality following urooncological operations (2022) Fiebig C, Kahlmeyer A, Bannert H, Taubert H, Wach S, Koneval L, Graf S, et al. Conference contribution Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer (BMC Cancer, (2021), 21, 1, (920), 10.1186/s12885-021-08656-0) (2021) Stuerken C, Moebus V, Milde-Langosch K, Schmatloch S, Fasching P, Rueschoff J, Stickeler E, et al. Journal article, Erratum TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer (2021) Stuerken C, Moebus V, Milde-Langosch K, Schmatloch S, Fasching P, Rueschoff J, Stickeler E, et al. Journal article Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials (2021) Denkert C, Seither F, Schneeweiss A, Link T, Blohmer JU, Just M, Wimberger P, et al. Journal article Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials (2021) Furlanetto J, Marmé F, Seiler S, Thode C, Untch M, Schmatloch S, Schneeweiss A, et al. Journal article BACH1 and HIF1 alpha predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC) (2021) Vladimirova V, Schneeweiss A, Jackisch C, Weber KE, Denkert C, Schmatloch S, Karn T, et al. Conference contribution Was machen Urologen in der Praxis? Ein erster „ungefilterter“ Blick auf die Versorgung (2021) Goebell P, El-Khadra S, Horstmann M, Kollenbach P, Luedecke G, Quack T, Rug M, et al. Journal article, Review article Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332) (2020) Hauke J, Ernst C, Fasching P, Jackisch C, Seither F, Klare P, Rhiem KE, et al. Conference contribution Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) (2020) Fasching P, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, et al. Journal article